BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?

Medtronic is positioned more favorably than Boston Scientific: fiscal Q1 2027 Cardiovascular revenue rose 18.9% organically, with Cardiac Ablation Solutions revenue up 88% globally and 139% in the U.S., gaining 9 share points and exceeding $2 billion in trailing-12-month sales. Medtronic's FY2027 EPS consensus is $5.97, up 8% year over year and revised 0.5% higher over 60 days, while Boston Scientific's 2026 EPS estimate fell 1.8% to $3.29 amid expected flat H2 2026 electrophysiology growth and mid-single-digit sequential U.S. sales declines. MDT gained 18.6% over three months and trades above its 50- and 200-day moving averages, versus BSX down 2.1% and below both averages; the article favors holding MDT and exiting BSX pending improved operational visibility.

Analysis

The actionable signal is relative execution, not the electrophysiology growth category itself. MDT's ablation momentum can create a self-reinforcing installed-base advantage: greater lab familiarity and procedural throughput increase disposable pull-through and make account conversion harder for BSX. This also raises near-term pressure on BSX gross margin if it responds with pricing, physician-training spend, or accelerated launch investment; consensus has begun to adjust but likely has not fully modeled a prolonged U.S. share-loss cycle.

For the next 1-3 months, MDT has a cleaner estimate-revision and momentum setup, while BSX faces asymmetric downside at the next guidance checkpoint if sequential U.S. procedure trends fail to stabilize. However, MDT's recent outperformance makes outright long exposure less attractive than a market-neutral relative-value expression. The key falsifier is a material deceleration in MDT's ablation growth or evidence that its share gains are merely supply-constrained competitor catch-up rather than durable conversion.

The underappreciated BSX issue is capital allocation: a large PEN transaction would shift investor focus from organic-growth quality to financing, integration, and synergy credibility precisely while two core U.S. cardiovascular franchises are under pressure. PEN holders should treat deal-spread behavior and regulatory timing as the near-term driver, rather than assume BSX's strategic rationale alone supports PEN's valuation. Over 6-18 months, BSX could become a recovery candidate if new PFA/ICE products restore lab workflow differentiation, but that is not a 2026 earnings catalyst.

Contrarian risk to the MDT bull case is that unusually rapid ablation growth embeds a difficult comparison base and may invite competitive pricing. A broad procedural-volume slowdown would disproportionately hurt high-expectation growth franchises, while BSX's international mix and diversified MedSurg base provide some downside offset. Maintain the trade only while MDT estimate revisions remain positive relative to BSX and quarterly U.S. EP growth continues to diverge.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral long MDT / short BSX pair, sized beta-neutral. Target 10-15% relative outperformance; exit if MDT U.S. ablation growth drops below 40% or BSX guides U.S. EP back to positive sequential growth.
• Avoid adding to standalone BSX ahead of its next earnings/guidance update. Reassess only after two consecutive quarters of stabilization in U.S. EP and WATCHMAN trends, or a clear margin-defense plan; this is a watch item rather than a bottom-fishing long.
• For MDT longs, use a trailing stop around a sustained break below its 200-day moving average and reduce into evidence of price concessions in ablation. The principal risk/reward is favorable operationally, but multiple risk is elevated after the recent rerating.
• Monitor PEN deal-spread and antitrust/closing milestones as an event-driven alert. Do not underwrite BSX acquisition synergies until financing terms, expected dilution, and integration cost disclosures permit a revised pro forma EPS and leverage model.